Merck said clesrovimab, if approved, would be the first and only single-dose immunization for infants regardless of weight designed to protect them for the duration of their first RSV season.

About clesrovimab (MK-1654) Clesrovimab (MK-1654) is an investigational, extended half-life monoclonal antibody (mAb) developed as a passive immunization for the prevention of RSV disease.

“We’ve stepped back into the world that we lived in before the [CDC’s vaccine advisory committee] was created,” said Dr.

Clesrovimab is a monoclonal antibody (mAb) that protects against RSV subtypes A and B. Merck investigators presented the results of two phase 2b/3 trials at IDWeek in October.

The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

Clesrovimab is a monoclonal antibody that is given as a shot to babies 8 months or younger who are born during or entering their first RSV season. The RSV season generally spans from October to March.

ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born ...

The shot, called clesrovimab and given the brand name Enflonsia, is made by Merck and joins two other interventions already on the market to protect babies against severe disease from RSV, a ...

About clesrovimab (MK-1654) Clesrovimab (MK-1654) is an investigational, extended half-life monoclonal antibody (mAb) developed as a passive immunization for the prevention of RSV disease.

The shot, called clesrovimab and given the brand name Enflonsia, is made by Merck and joins two other interventions already on the market to protect babies against severe disease from RSV, a ...

The shot, called clesrovimab and given the brand name Enflonsia, is made by Merck and joins two other interventions already on the market to protect babies against severe disease from RSV, a ...